[对治疗成人恶性淋巴瘤的CAR-T细胞治疗的当前和未来前景]
1Department of Medical Oncology, Tokyo Metropolitan Cancer and Infectious.
[Rinsho ketsueki] The Japanese journal of clinical hematology
|October 29, 2023
概括
化学抗原受体T细胞 (CAR-T) 疗法对复发性/耐药性扩散性大B细胞淋巴瘤 (DLBCL) 显示出前景. 需要更明确的指导方针来选择最佳的CAR-T代理和时间,以改善患者的治疗结果.
科学领域:
- 在瘤学瘤学.
- 免疫治疗是一种免疫疗法.
- 血液学 血液学 血液学
背景情况:
- 化学抗原受体T细胞 (CAR-T) 治疗对预后不佳的复发性/耐药性扩散性大B细胞淋巴瘤 (R/R DLBCL) 患者来说是一个显著的进步.
- 经FDA批准的CD19 CAR-T疗法在关键试验和现实数据中显示出高完全响应率 (40-60%) 和长期缓解.
研究的目的:
- 为了解决日本R/R DLBCL和R/R毛囊淋巴瘤中CAR-T剂选择和时间的明确指导方针的缺乏.
- 强调需要在优化CAR-T治疗和监测长期不良事件方面进行机构合作.
主要方法:
- 对CD19 CAR-T疗法 (Yescarta®,Kymriah®,Breyanzi®) 的关键试验数据和现实研究的审查.
- 在日本对R/R DLBCL和R/R毛囊淋巴瘤的CAR-T疗法的当前治疗实践和指导限制的分析.
主要成果:
- 在日本,CAR-T疗法已被批准用于R/R DLBCL (2019) 和R/R毛囊淋巴瘤 (2022).
- 目前的机构标准各不相同,缺乏对CAR-T剂的选择和治疗时间的标准指南.
- 优化治疗策略需要考虑T细胞健康和瘤负担,需要转诊机构的合作.
结论:
- 标准化指导方针对于优化CAR-T治疗选择和时间在R/R DLBCL和R/R毛囊淋巴瘤中至关重要.
- 密切的机构合作对于有效的治疗计划和CAR-T治疗后的长期不良事件监测至关重要.
更多相关视频
08:46A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells
Published on: November 12, 2019
53.3K
09:34Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography
Published on: February 17, 2022
3.4K
相关概念视频
Targeted Cancer Therapies
7.7K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.7K
Tumor Immunotherapy
538
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
538
Treatment Resistant Cancers
3.3K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K
Bone Marrow Sampling and Transplants
341
Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
341
